Join Our Telegram channel to stay up to date on breaking news coverage
Over this past month, CurveDAO (CRV) has joined market losers, suffering a sharp decline. The bearish momentum caused the token to plummet more than 14%. This was after the token broke past the recent $0.5 high and met strong resistance. Despite the fall, investors in the CurveDAO DeFi platform are still optimistic, expecting the token to push towards ATH with the Bitcoin halving momentum.
As we’ve seen, the bearish correction even has AI tokens declining, but InQubeta (QUBE) is an exception. The fast-rising AI crypto has outperformed many of its competition with an explosive presale performance. During the event, QUBE skyrocketed by 300% and achieved multiple milestones that put InQubeta on the radar of top investors in the industry. Thanks to the recent momentum it’s been gaining, analysts are confident in InQubeta’s potential to rival top altcoins like Injective (INJ).
Let’s explore the performance of CurveDAO and the recent momentum of InQubeta.
InQubeta’s (QUBE) Growth Momentum Hints At Upcoming Explosive Gains For Investors
InQubeta could easily dominate the market as the best crypto to invest in for long-term gains. Why? This highly anticipated cryptocurrency platform provides investors with AI investment opportunities while helping AI startups raise venture capital. InQubeta uses fractionalized equity-based NFTs to make it more affordable. This is why investors have recognized them as the best NFTs to invest in for DeFi users.
InQubeta has been able to pull the support of large investors because, apart from AI investment opportunities, they get more perks. InQubeta has a decentralized governance program that allows token holders to vote for the platform’s future. A staking feature also rewards QUBE holders for locking their tokens. Notice how all benefits revolve around the QUBE token? This is why investors have been scrambling to get QUBE throughout the presale.
This high demand for QUBE has helped the platform pull over $13.2 million in investment liquidity. This is way more than most established altcoins delivered during their presale, convincing investors of its potential to outperform tokens like Injective. QUBE surged from $0.007 to $0.028 during the presale, delivering over 300% to early investors. Since QUBE has yet to launch, its performance has sparked bullish expectations. Analysts are optimistic that once QUBE lists on top-tier exchanges, it could skyrocket to $1, making it the best crypto to invest in this year. The presale is in its final stage; investors can get it for just $0.028.
CurveDAO’s (CRV) 14% Decline Triggers Doubt In Investors
CurveDAO came into the limelight in March as a market leader with gains of over 18%. Its quick rise was thanks to a boost in its on-chain developments. CurveDAO’s focus on reducing slippage and offering access to liquidity played a big part in its rise. The rollercoaster performance of the market has affected many tokens, sinking them to lower prices. According to price experts, CurveDAO has been affected by this bearish trend.
So far, bearish momentum has caused CRV to decline by approximately 14% over the past seven days. The fall has positioned CurveDAO among the biggest losers during the bearish correction. While CRV has previously powered towards the $1 mark before falling, it’s showing no sign of recovery and a weak upward surge. CRV is currently down 95% from its all-time high, and its recent performance has sparked doubts about the token’s ability to reclaim its ATH of $60.
Conclusion
March was a bearish month for the cryptocurrency industry, and CurveDAO’s performance shows that it’s still vulnerable to both positive and negative trends. While CRV has declined, it still shows potential to recover despite doubts. For investors who are trying to avoid volatility in the markets, InQubeta is an excellent investment choice. Its offerings of the best NFTs to invest in make it a promising alternative to other bearish altcoins.
Join Our Telegram channel to stay up to date on breaking news coverage
